Patents by Inventor Anthony Sauve

Anthony Sauve has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9790252
    Abstract: Disclosed are halogenated 2-deoxy-lactone, 2?-deoxy-nucleosides, and derivatives thereof, for example, a compound of formula (I). Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one compound or salt of the invention, and a method of treating a disorder is selected from the group consisting of an abnormal cellular proliferation, a viral infection, and an autoimmune disorder.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: October 17, 2017
    Assignee: CORNELL UNIVERSITY
    Inventors: Anthony A. Sauve, Yana Cen
  • Patent number: 9603862
    Abstract: The invention provides a method of increasing a deacetylase activity of SIRT5 by contacting SIRT5 with an agent that binds SIRT5 and reduces the Km of SIRT5 for a substrate, thereby increasing the deacetylase activity of SIRT5. The invention also provides a method for treating a urea cycle disorder in a mammal, as well as a method of assaying a sirtuin modulator.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: March 28, 2017
    Assignee: CORNELL UNIVERSITY
    Inventors: Anthony Sauve, Yana Cen
  • Publication number: 20160310517
    Abstract: The invention relates to compositions of nicotinoyl ribosides and nicotinamide riboside derivatives and their methods of use. In some embodiments, the invention relates to methods of snaking nicotinoyl ribosides. In some embodiments, the invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinoyl riboside. In further embodiments, the invention relates to methods of using nicotinoyl ribosides and nicotinamide riboside derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival.
    Type: Application
    Filed: April 25, 2016
    Publication date: October 27, 2016
    Inventors: Anthony A. Sauve, Tianle Yang Redanz
  • Patent number: 9321797
    Abstract: The invention relates to compositions of nicotinoyl ribosides and nicotinamide riboside derivatives and their methods of use. In some embodiments, the invention relates to methods of making nicotinoyl ribosides. In some embodiments, the invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinoyl riboside. In further embodiments, the invention relates to methods of using nicotinoyl ribosides and nicotinamide riboside derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: April 26, 2016
    Assignee: CORNELL UNIVERSITY
    Inventors: Anthony A. Sauve, Tianle Yang Redanz
  • Patent number: 9322049
    Abstract: The invention provides a method of increasing a deacetylated activity of SIRT6 by contacting SIRT6 with an agent that binds SIRT6 and reduces the Km of SIRT6 for a substrate, thereby increasing the deacetylase activity of SIRT6. The invention also provides compounds of the formulas (II) and (III).
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: April 26, 2016
    Assignee: CORNELL UNIVERSITY
    Inventors: Anthony Sauve, Ping Xu
  • Patent number: 9290791
    Abstract: The invention provides a method of preparing a sirtuin complex, a method for detecting a sirtuin in a sample, and a method of screening for compounds which inhibit the deacetylase activity of a sirtuin. The method includes (a) providing a sirtuin substrate having the formula: (b) providing NAD+ or an NAD+ analog having the formula: and (c) providing a sirtuin, wherein R1-R4, A1, A2, and n are as defined herein.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: March 22, 2016
    Assignee: CORNELL UNIVERSITY
    Inventors: Anthony A. Sauve, Yana Cen
  • Publication number: 20150174148
    Abstract: The invention provides a method of preventing or treating hearing loss in a mammal in need thereof. The method involves administering to the mammal an agent that increases intracellular NAD+ in the mammal. The invention also provides a method of determining if a compound acts as a neuroprotective agent.
    Type: Application
    Filed: July 15, 2013
    Publication date: June 25, 2015
    Inventors: Kevin Brown, Anthony Sauve, Samie Jaffrey
  • Patent number: 9000147
    Abstract: The invention relates to compositions of nicotinoyl ribosides and nicotinamide riboside derivatives and their methods of use. In some embodiments, the invention relates to methods of making nicotinoyl ribosides. In some embodiments, the invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinoyl riboside. In further embodiments, the invention relates to methods of using nicotinoyl ribosides and nicotinamide riboside derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival.
    Type: Grant
    Filed: January 17, 2012
    Date of Patent: April 7, 2015
    Assignee: Cornell University
    Inventors: Anthony A. Sauve, Tianle Yang Redanz
  • Publication number: 20150072950
    Abstract: The invention relates to compositions of nicotinoyl ribosides and nicotinamide riboside derivatives and their methods of use. In some embodiments, the invention relates to methods of making nicotinoyl ribosides. In some embodiments, the invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinoyl riboside. In further embodiments, the invention relates to methods of using nicotinoyl ribosides and nicotinamide riboside derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival.
    Type: Application
    Filed: November 17, 2014
    Publication date: March 12, 2015
    Inventors: Anthony A. SAUVE, Tianle Yang REDANZ
  • Patent number: 8835467
    Abstract: Compounds are disclosed which inhibit SIR2 base exchange more than deacetylation, thus enhancing SIR2 deacetylation activity. Methods of using the compounds for enhancing SIR2 deacetylation activity and increasing longevity of an organism are also disclosed. Methods for screening for compounds that enhance SIR2 deacetylation activity and increase longevity of an organism are additionally disclosed.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: September 16, 2014
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Vern L. Schramm, Anthony A. Sauve
  • Publication number: 20130231351
    Abstract: Compounds are disclosed which inhibit SIR2 base exchange more than deacetylation, thus enhancing SIR2 deacetylation activity. Methods of using the compounds for enhancing SIR2 deacetylation activity and increasing longevity of an organism are also disclosed. Methods for screening for compounds that enhance SIR2 deacetylation activity and increase longevity of an organism are additionally disclosed.
    Type: Application
    Filed: January 23, 2013
    Publication date: September 5, 2013
    Applicant: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Vern L. Schramm, Anthony A. Sauve
  • Publication number: 20130065248
    Abstract: The invention provides a method of preparing a sirtuin complex. The invention also provides a method of detecting a sirtuin in a sample comprising use of the aforesaid sirtuin complex.
    Type: Application
    Filed: May 18, 2011
    Publication date: March 14, 2013
    Applicant: CORNELL UNIVERSITY
    Inventors: Anthony A. SAUVE, Yana CEN
  • Patent number: 8383653
    Abstract: Compounds are disclosed which inhibit SIR2 base exchange more than deacetylation, thus enhancing SIR2 deacetylation activity. Methods of using the compounds for enhancing SIR2 deacetylation activity and increasing longevity of an organism are also disclosed. Methods for screening for compounds that enhance SIR2 deacetylation activity and increase longevity of an organism are additionally disclosed.
    Type: Grant
    Filed: June 30, 2004
    Date of Patent: February 26, 2013
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Vern L. Schramm, Anthony A. Sauve
  • Publication number: 20130029930
    Abstract: The invention provides a method of increasing a deacetylated activity of SIRT6 by contacting SIRT6 with an agent that binds SIRT6 and reduces the Km of SIRT6 for a substrate, thereby increasing the deacetylase activity of SIRT6. The invention also provides compounds of the formulas (II) and (III).
    Type: Application
    Filed: December 14, 2010
    Publication date: January 31, 2013
    Applicant: CORNELL UNIVERSITY
    Inventors: Anthony Sauve, Ping Xu
  • Publication number: 20120329748
    Abstract: The invention provides a method of increasing a deacetylase activity of SIRT5 by contacting SIRT5 with an agent that binds SIRT5 and reduces the Km of SIRT5 for a substrate, thereby increasing the deacetylase activity of SIRT5. The invention also provides a method for treating a urea cycle disorder in a mammal, as well as a method of assaying a sirtuin modulator.
    Type: Application
    Filed: December 14, 2010
    Publication date: December 27, 2012
    Applicant: CORNELL UNIVERSITY
    Inventors: Anthony Sauve, Yana Cen
  • Publication number: 20120108535
    Abstract: Disclosed are halogenated 2-deoxy-lactone, 2?-deoxy-nucleosides, and derivatives thereof, for example, a compound of formula (I). Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one compound or salt of the invention, and a method of treating a disorder is selected from the group consisting of an abnormal cellular proliferation, a viral infection, and an autoimmune disorder.
    Type: Application
    Filed: July 1, 2010
    Publication date: May 3, 2012
    Applicant: CORNELL UNIVERSITY
    Inventors: Anthony A. Sauve, Yana Cen
  • Patent number: 7741295
    Abstract: A novel compound, 2?/3?-O-acetyl-ADP-ribose, is provided. The compound is a mixture of the 2? and 3? regioisomers of O-acetyl-ADP ribose, and is formed nonenzymatically from 2?-O-acetyl-ADP-ribose, which is the newly discovered product of the reaction of Sir2 enzymes with acetylated peptides and NAD+. Analogs of 2?/3?-O-acetyl-ADP-ribose are also provided. Additionally, methods of preparing 2?/3?-O-acetyl-ADP-ribose, methods of determining whether a test compound is an inhibitor of a Sir2 enzyme, methods of detecting Sir2 activity in a composition, methods of deacetylating an acetylated peptide, and methods of inhibiting the deacetylation of an acetylated peptide are provided. Prodrugs of 2?/3?-O-acetyl-ADP-ribose are also provided.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: June 22, 2010
    Assignees: Albert Einstein College of Medicine of Yeshiva University, The Johns Hopkins University
    Inventors: Vern L. Schramm, Jef D. Boeke, Anthony Sauvé, Ivana Celic
  • Patent number: 7504489
    Abstract: The present invention provides compounds having the formula: wherein A is chosen from a nitrogen-, oxygen-, or sulfur-linked aryl, alkyl, cyclic, or heterocyclic group; both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen; and D is a primary alcohol, a hydrogen, or an oxygen, nitrogen, carbon, or sulfur linked to phosphate, a phosphoryl group, a pyrophosphoryl group, or adenosine monophosphate through a phosphodiester or carbon-, nitrogen-, or sulfur-substituted phosphodiester bridge, or to adenosine diphosphate through a phosphodiester or carbon-, nitrogen-, or sulfur-substituted pyrophosphodiester bridge. The present invention also provides pharmaceutical compositions containing the above compounds, methods of using the above compounds as pharmaceuticals, and processes for preparing the above compounds.
    Type: Grant
    Filed: December 5, 2005
    Date of Patent: March 17, 2009
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Anthony A. Sauve, Vern L. Schramm
  • Publication number: 20090068695
    Abstract: A novel compound, 2?/3?-O-acetyl-ADP-ribose, is provided. The compound is a mixture of the 2? and 3? regioisomers of O-acetyl-ADP ribose, and is formed nonenzymatically from 2?-O-acetyl-ADP-ribose, which is the newly discovered product of the reaction of Sir2 enzymes with acetylated peptides and NAD+. Analogs of 2?/3?-O-acetyl-ADP-ribose are also provided. Additionally, methods of preparing 2?/3?-O-acetyl-ADP-ribose, methods of determining whether a test compound is an inhibitor of a Sir2 enzyme, methods of detecting Sir2 activity in a composition, methods of deacetylating an acetylated peptide, and methods of inhibiting the deacetylation of an acetylated peptide are provided. Prodrugs of 2?/3?-O-acetyl-ADP-ribose are also provided.
    Type: Application
    Filed: September 5, 2008
    Publication date: March 12, 2009
    Inventors: Vern L. Schramm, Jef D. Boeke, Anthony Sauve, Ivana Celic
  • Publication number: 20090012148
    Abstract: Compounds disclosed herein may be used in disclosed methods for reducing the amount of cholesterol in a cell, for treating a patient suffering from a disorder characterized by cellular accumulation of cholesterol (such as Niemann-Pick Disease Type C or atherosclerosis), and/or for treating or preventing phospholipidosis. In some embodiments, the compounds may include a pyrrolone or triazine moiety.
    Type: Application
    Filed: October 31, 2006
    Publication date: January 8, 2009
    Inventors: Frederick R. Maxfield, Anthony Sauve